AR061026A1 - Compuesto glicitol c-fenilo y preparacion farmaceutica - Google Patents
Compuesto glicitol c-fenilo y preparacion farmaceuticaInfo
- Publication number
- AR061026A1 AR061026A1 ARP070102161A ARP070102161A AR061026A1 AR 061026 A1 AR061026 A1 AR 061026A1 AR P070102161 A ARP070102161 A AR P070102161A AR P070102161 A ARP070102161 A AR P070102161A AR 061026 A1 AR061026 A1 AR 061026A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- substituted
- hydroxyl
- substituents selected
- alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 24
- 125000001424 substituent group Chemical group 0.000 abstract 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 13
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 8
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 6
- 229910052757 nitrogen Inorganic materials 0.000 abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 5
- 125000004429 atom Chemical group 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 abstract 4
- 239000000470 constituent Substances 0.000 abstract 4
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 4
- 229920006395 saturated elastomer Polymers 0.000 abstract 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 3
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 3
- -1 morpholino, pyrrolidin-1-yl-carbonyl Chemical group 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 2
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 abstract 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 abstract 1
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 abstract 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
Abstract
Reivindicacion 1: Un compuesto de glicitol C-fenilo caracterizado porque está representado por la formula (1) o una sal farmacéuticamente aceptable del mismo, o un hidrato del mismo en donde R1 y R2 son iguales o diferentes y representan un átomo de H, un grupo hidroxilo, un grupo alquilo C1-6, alcoxilo C1-6 o un átomo halogeno; R3 es un átomo de H, un grupo alquilo C1-6, alcoxilo C1-6 o un átomo halogeno; Y es un grupo alquileno C1-6, -O(CH2)n- (n es un entero de valor 1 a 4) o un grupo alquenileno C2-6, con la condicion que cuando Z es -NHC(=NH)NH2 o -NHCON(RB)RC, n no es 1, Z es -CONHRA, -NHC(=NH)NH2 o -NHCON(RB)RC, formulas (2) donde RA es un grupo alquilo C1-6 sustituido con 1 a 3 sustituyentes seleccionados del grupo que consiste de un grupo hidroxilo, amino y un grupo carbamoilo, RB es(1) un átomo de hidrogeno, (2) un grupo alquilo C1-6 que puede ser sustituido con 1 a 3 sustituyentes seleccionados del Grupo A, (3) un grupo cicloalquilo C3-12 que puede ser sustituido con 1 a 3 sustituyentes seleccionados de un grupo hidroxilo y un grupo hidroxialquilo C1-6, (4) un grupo heterocicloalquilo de 3 a 12 miembros o un grupo heteroarilo de 5 a 13 miembros que puede ser parcialmente saturado cada uno de los cuales contiene uno a tres átomo(s) constituyente(s) del anillo seleccionados del grupo que consiste de O, N, S, SO2, CO y NR10 (R10 es un átomo de hidrogeno, un grupo alquilo C1-6, un grupo fenilalquilo C1-6 o un grupo alcoxicarbonilo C2-6) , y puede ser sustituido con 1 a 3 sustituyentes seleccionados del grupo que consiste de un grupo hidroxilo y un grupo hidroxialquilo C1-6, o (5) un grupo arilo C6-13 que puede ser parcialmente saturado y puede ser sustituido con 1 o 2 sustituyentes seleccionados de un grupo hidroxilo, y un grupo alquilo C1-6, un grupo fenilalquilo C1-6 y un grupo alquilsulfonilo C1-6 cada uno de los cuales puede ser sustituido con grupo(s) hidroxilo en donde Grupo A consiste de un átomo halogeno, un grupo hidroxilo, alcoxilo C1-6, el cual puede ser sustituido con un grupo(s) hidroxilo, carboxilo, alcoxicarbonilo C2-6, carbamoilo, amino, alquilamino C1-6, dialquilamino C1-6, acilamino C2-6, alquiltio C1-6 que puede ser sustituido con grupo(s) hidroxilo, un grupo fenoxilo, un grupo fenilo que puede ser sustituido con 1 a 3 sustituyentes seleccionados del Grupo B (el Grupo B consiste de un grupo hidroxilo, un átomo halogeno, un grupo alcoxilo C1-6, alquilo C1-6 que puede ser sustituido con un grupo(s) hidroxilo, alquiltio C1-6, tienilo, feniltio que puede ser sustituido con un grupo(s) hidroxilo o un grupo(s) hidroxialquilo C1-6, y un grupo piperidino que puede ser sustituido con grupo(s) hidroxilo o grupo(s) hidroxialquilo C1-6), un grupo cicloalquilo C3-12 que puede ser sustituido con 1 a 3 sustituyentes seleccionados del grupo que consiste de un grupo hidroxilo y un grupo hidroxialquilo C1-6, un grupo heterocicloalquilo de 3 a 12 miembros o un grupo heteroarilo de 5 a 13 miembros que puede ser parcialmente saturado, cada uno de los cuales contiene uno a tres átomo(s) constituyentes del anillo seleccionado del grupo que consiste de O, N, S, SO2, CO y NR10 (R10 es un átomo de hidrogeno, un grupo alquilo C1-6, fenilalquilo C1-6 o un grupo alcoxicarbonilo C2-6), y puede ser sustituido con 1 a 3 sustituyentes seleccionados del grupo que consiste de un grupo hidroxilo y un grupo hidroxialquilo C1-6, y CONRB1RB2 en donde RB1 y RB2 junto con el átomo de nitrogeno al cual están unidos forman un grupo heterocicloalquilo de 5 a 6 miembros que puede contener como otro átomo constituyente del anillo un átomo de oxígeno, un átomo de nitrogeno o un átomo de azufre y puede ser sustituido con 1 o 2 sustituyentes seleccionados del grupo que consiste de un grupo alquilo C1-6 que puede ser sustituido con un grupo(s) hidroxilo, alcoxicarbonilo C2-6 y un grupo fenilalquilo C1-6, RC es un átomo de hidrogeno, un grupo alquilo C1-6 que puede ser sustituido con 1 o 2 sustituyentes seleccionados del grupo que consiste de un grupo hidroxilo, dialquilamino C1-6, alcoxicarbonilo C2-6 y alcoxilo C1-6, o un grupo cicloalquilo C3-12 que puede ser sustituido con grupo(s) hidroxilo, y RB y RC junto con el átomo de nitrogeno al cual están unidos pueden formar un grupo heterocicloalquilo de 3 a 12 miembros o un grupo heteroarilo de 5 a 13 miembros el cual puede ser parcialmente saturado, cada uno de los cuales puede contener 1 o 2 átomos constituyentes del anillo seleccionado de O, N, NR11, S, SO2 y CO y el cual puede ser sustituido con 1 o 2 sustituyentes seleccionados del grupo que consiste de un grupo hidroxilo, alcoxicarbonilo C2-6, carbamoilo, acil C2-6-alquil C1-6-amino, dialquilaminocarbonilo C1-6, un grupo pirrolidinilo, morfolino, pirrolidin-1-il-carbonilo, alquilo C1-6 que puede ser sustituido con 1 a 3 sustituyentes seleccionados del grupo que consiste de un grupo hidroxilo, pirrolidin-1-ilo, fenilo, y alcoxicarbonilo C2-6, y un grupo fenilo que puede ser sustituido con 1 a 3 sustituyentes seleccionados del grupo que consiste de un grupo alquilo C1-6, alcoxilo C1-6 y un átomo halogeno, en donde R11 es un átomo de hidrogeno, un grupo acilo C2-6, fenilo que puede ser sustituido con un grupo(s) hidroxilo, un grupo piridilo, furilcarbonilo, oxolanilcarbonilo, alcoxicarbonilo C2-6 o un grupo alquilo C1-6 que puede ser sustituido con 1 o 2 sustituyentes seleccionados del grupo que consiste de un grupo hidroxilo, fenilo, dialquilamino C1-6, morfolino y un grupo pirrolidin-1-il-carbonilo, y RD es un átomo de hidrogeno o un grupo alquilo C1-6 que pueden ser sustituidos con 1 o sustituyentes del grupo que consiste de un grupo hidroxilo, un grupo cicloalquilo C3-12, fenilo que puede ser sustituido con un grupo(s) hidroxilo, un grupo piridilo, alcoxicarbonilo C2-6, imidazolilo y un grupo 1-bencilimidazolilo, y RDA es un átomo de hidrogeno o un grupo alquilo C1-6.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006139891 | 2006-05-19 | ||
| JP2006200033 | 2006-07-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061026A1 true AR061026A1 (es) | 2008-07-30 |
Family
ID=38617514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102161A AR061026A1 (es) | 2006-05-19 | 2007-05-18 | Compuesto glicitol c-fenilo y preparacion farmaceutica |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7973012B2 (es) |
| EP (1) | EP2076503B1 (es) |
| JP (1) | JP5067644B2 (es) |
| KR (1) | KR20090016456A (es) |
| CN (1) | CN101490028B (es) |
| AR (1) | AR061026A1 (es) |
| AU (1) | AU2007252432B2 (es) |
| BR (1) | BRPI0711949A2 (es) |
| CA (1) | CA2652707A1 (es) |
| MX (1) | MX2008014512A (es) |
| NO (1) | NO20084830L (es) |
| NZ (1) | NZ573687A (es) |
| RU (1) | RU2437876C2 (es) |
| TW (1) | TW200812995A (es) |
| WO (1) | WO2007136116A2 (es) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8198464B2 (en) | 2006-12-21 | 2012-06-12 | Astellas Pharma Inc. | Method for producing C-glycoside derivative and intermediate for synthesis thereof |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| NO2187742T3 (es) | 2007-08-23 | 2018-03-24 | ||
| US20090324569A1 (en) * | 2007-11-21 | 2009-12-31 | Decode Genetics Ehf | Biaryl pde4 inhibitors for treating inflammatory, cardiovascular and cns disorders |
| UA101004C2 (en) | 2007-12-13 | 2013-02-25 | Теракос, Инк. | Derivatives of benzylphenylcyclohexane and use thereof |
| JP5302900B2 (ja) * | 2008-01-31 | 2013-10-02 | アステラス製薬株式会社 | 脂肪性肝疾患の治療用医薬組成物 |
| BRPI0913129A2 (pt) | 2008-05-22 | 2016-01-05 | Bristol Myers Squibb Co | método para tratamento de hiperuricemia empregando um inibidor de sglt2 e composição contendo o mesmo |
| BRPI0916769A2 (pt) | 2008-07-15 | 2017-09-26 | Theracos Inc | derivados de benzilbenzeno deuterados e métodos de uso |
| HUE029970T2 (en) | 2008-08-22 | 2017-04-28 | Theracos Sub Llc | Processes for the preparation of sglt2 inhibitors |
| MX344264B (es) * | 2009-02-13 | 2016-12-09 | Boehringer Ingelheim Int Gmbh * | Inhibidor de sglt-2 para el tratamiento de diabetes mellitus tipo 1, diabetes mellitus tipo 2, tolerancia deteriorada a la glucosa o hiperglucemia. |
| US8466113B2 (en) | 2009-02-23 | 2013-06-18 | Taisho Pharmaceutical Co., Ltd. | 4-isopropylphenyl glucitol compounds as SGLT1 inhibitors |
| UY32919A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos |
| JP5696156B2 (ja) | 2009-11-02 | 2015-04-08 | ファイザー・インク | ジオキサ−ビシクロ［３．２．１］オクタン−２，３，４−トリオール誘導体 |
| WO2011070592A2 (en) | 2009-12-09 | 2011-06-16 | Panacea Biotec Ltd. | Novel sugar derivatives |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8575114B2 (en) | 2010-03-23 | 2013-11-05 | Albany Molecular Research, Inc. | SGLT-2 inhibitors, methods of making them, and uses thereof |
| WO2011153712A1 (en) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| JP2013224263A (ja) * | 2010-08-19 | 2013-10-31 | Taisho Pharmaceutical Co Ltd | ４−イソプロピルフェニルグルシトール化合物 |
| WO2012023598A1 (ja) | 2010-08-20 | 2012-02-23 | 大正製薬株式会社 | ４－イソプロピルフェニル グルシトール化合物の結晶形及びその製造方法 |
| JP5817317B2 (ja) * | 2010-08-20 | 2015-11-18 | 大正製薬株式会社 | ４−イソプロピルフェニルグルシトール化合物を有効成分として含有することを特徴とする糖尿病の予防又は治療剤 |
| US9161945B2 (en) | 2010-08-20 | 2015-10-20 | Taisho Pharmaceutical Co., Ltd. | 4-isopropyl-6-methoxyphenyl glucitol compound |
| CN102453026A (zh) * | 2010-10-27 | 2012-05-16 | 上海艾力斯医药科技有限公司 | C-芳基葡糖苷衍生物、制备方法及其应用 |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US9522931B2 (en) * | 2011-05-20 | 2016-12-20 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of SGLT-2 |
| US9562029B2 (en) | 2011-06-25 | 2017-02-07 | Xuanzhu Pharma Co., Ltd. | C-glycoside derivatives |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9018249B2 (en) | 2011-09-13 | 2015-04-28 | Panacea Biotec Limited | SGLT inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
| UA113086C2 (xx) | 2012-05-10 | 2016-12-12 | Піразольні сполуки як інгібітори sglt1 | |
| TW201425326A (zh) | 2012-10-05 | 2014-07-01 | Lilly Co Eli | 新穎脲化合物 |
| FR2998202B1 (fr) * | 2012-11-19 | 2015-04-17 | Centre Nat Rech Scient | Soudage heterogene aluminium/cuivre |
| EP3489226B1 (en) | 2012-11-20 | 2021-02-17 | Lexicon Pharmaceuticals, Inc. | Inhibitors of sodium glucose cotransporter 1 |
| AU2014213251B2 (en) | 2013-02-04 | 2017-07-20 | Taisho Pharmaceutical Co., Ltd. | Prophylactic or therapeutic drug for constipation |
| HK1215398A1 (zh) | 2013-04-05 | 2016-08-26 | 勃林格殷格翰国际有限公司 | 依帕列净的治疗用途 |
| CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| PT2986304T (pt) | 2013-04-18 | 2022-02-25 | Boehringer Ingelheim Int | Composição farmacêutica, métodos para o tratamento e suas utilizações |
| CN105611920B (zh) | 2013-10-12 | 2021-07-16 | 泰拉科斯萨普有限责任公司 | 羟基-二苯甲烷衍生物的制备 |
| AR098670A1 (es) | 2013-11-08 | 2016-06-08 | Lilly Co Eli | Inhibidor de sglt1 |
| US9315438B2 (en) | 2014-01-03 | 2016-04-19 | Xuanzhu Pharma Co., Ltd | Optically pure benzyl-4-chlorophenyl-C-glucoside derivative |
| WO2017141202A1 (en) | 2016-02-17 | 2017-08-24 | Lupin Limited | Complex of sglt2 inhibitor and process for preparation thereof |
| CN107540706A (zh) * | 2016-06-28 | 2018-01-05 | 山东诚创医药技术开发有限公司 | 伊格列净中间体的制备方法 |
| CN106632223B (zh) * | 2016-08-24 | 2019-04-23 | 浙江美诺华药物化学有限公司 | 2-(3-溴-4-(3-氟苄氧基)苯基)-1,3-二氧戊环及其制备方法 |
| MA46742A (fr) | 2016-11-10 | 2019-09-18 | Boehringer Ingelheim Int | Composition pharmaceutique, méthodes de traitement et leurs utilisations |
| CN108033876A (zh) * | 2017-12-20 | 2018-05-15 | 江汉大学 | 一种5-溴-2-氯苯甲醛的制备方法 |
| CN110066302B (zh) * | 2018-01-23 | 2022-12-27 | 广东东阳光药业有限公司 | 吡喃葡萄糖基衍生物及其用途 |
| CN111630058B (zh) | 2018-01-31 | 2022-02-15 | 广东东阳光药业有限公司 | 吡喃葡萄糖基衍生物及其用途 |
| CN108610385A (zh) * | 2018-04-23 | 2018-10-02 | 中国科学院成都生物研究所 | 一种钠-葡萄糖协同转运蛋白1抑制剂的药物用途 |
| US12324812B2 (en) | 2019-07-10 | 2025-06-10 | Sunshine Lake Pharma Co., Ltd. | Glucopyranosyl derivatives and their uses |
| ES3040243T3 (en) | 2020-05-15 | 2025-10-29 | Shanghai Zheye Biotechnology Co Ltd | Aryl glucoside derivative and use thereof in drug |
| WO2025245592A1 (en) * | 2024-05-31 | 2025-12-04 | Aché Laboratórios Farmacêuticos S.A. | Multi-target compounds, process for the preparation of the compounds, intermediates, pharmaceutical composition, pharmaceutically acceptable salts, combination, medicament, use of a compound and method of treatment |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2176600T3 (es) | 1996-12-26 | 2002-12-01 | Tanabe Seiyaku Co | Derivado de la propiofenona y procedimientos para su preparacion. |
| WO1998031697A1 (en) | 1997-01-15 | 1998-07-23 | Sankyo Company, Limited | Aryl c-glycoside compounds and sulfated esters thereof |
| PH12000002657B1 (en) * | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| EP1270584B1 (en) | 2000-03-17 | 2005-12-07 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives |
| US6683056B2 (en) * | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
| CA2448741C (en) | 2001-05-30 | 2010-06-22 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor |
| DE60332743D1 (de) | 2002-08-08 | 2010-07-08 | Kissei Pharmaceutical | Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung |
| JP2004137245A (ja) | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
| JP4606876B2 (ja) | 2002-08-27 | 2011-01-05 | キッセイ薬品工業株式会社 | ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途 |
| JPWO2004050122A1 (ja) | 2002-12-04 | 2006-03-30 | キッセイ薬品工業株式会社 | 高血糖症に起因する疾患の予防又は治療剤 |
| KR101001848B1 (ko) * | 2003-03-14 | 2010-12-17 | 고토부키 세이야쿠 가부시키가이샤 | Ｃ-글리코시드 유도체 또는 이의 염, 및 이를 포함하는 의약 조성물 |
| IL218714A (en) | 2004-03-16 | 2013-02-28 | Boehringer Ingelheim Int | Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof |
| DE102004028241B4 (de) | 2004-06-11 | 2007-09-13 | Sanofi-Aventis Deutschland Gmbh | Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel |
| TW200637839A (en) * | 2005-01-07 | 2006-11-01 | Taisho Pharmaceutical Co Ltd | 1-thio-d-glucitol derivatives |
-
2007
- 2007-05-18 RU RU2008150383/04A patent/RU2437876C2/ru not_active IP Right Cessation
- 2007-05-18 CA CA002652707A patent/CA2652707A1/en not_active Abandoned
- 2007-05-18 MX MX2008014512A patent/MX2008014512A/es active IP Right Grant
- 2007-05-18 JP JP2009510714A patent/JP5067644B2/ja not_active Expired - Fee Related
- 2007-05-18 TW TW096118086A patent/TW200812995A/zh unknown
- 2007-05-18 BR BRPI0711949-6A patent/BRPI0711949A2/pt not_active IP Right Cessation
- 2007-05-18 EP EP07744087.3A patent/EP2076503B1/en active Active
- 2007-05-18 WO PCT/JP2007/060653 patent/WO2007136116A2/en not_active Ceased
- 2007-05-18 KR KR1020087028695A patent/KR20090016456A/ko not_active Ceased
- 2007-05-18 AU AU2007252432A patent/AU2007252432B2/en not_active Ceased
- 2007-05-18 US US12/301,463 patent/US7973012B2/en not_active Expired - Fee Related
- 2007-05-18 AR ARP070102161A patent/AR061026A1/es not_active Application Discontinuation
- 2007-05-18 CN CN2007800271552A patent/CN101490028B/zh not_active Expired - Fee Related
- 2007-05-18 NZ NZ573687A patent/NZ573687A/en not_active IP Right Cessation
-
2008
- 2008-11-17 NO NO20084830A patent/NO20084830L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009537509A (ja) | 2009-10-29 |
| MX2008014512A (es) | 2008-11-27 |
| US7973012B2 (en) | 2011-07-05 |
| CN101490028A (zh) | 2009-07-22 |
| BRPI0711949A2 (pt) | 2012-01-17 |
| KR20090016456A (ko) | 2009-02-13 |
| CN101490028B (zh) | 2013-02-06 |
| NO20084830L (no) | 2009-02-19 |
| CA2652707A1 (en) | 2007-11-29 |
| WO2007136116A2 (en) | 2007-11-29 |
| EP2076503B1 (en) | 2013-07-17 |
| TW200812995A (en) | 2008-03-16 |
| JP5067644B2 (ja) | 2012-11-07 |
| RU2437876C2 (ru) | 2011-12-27 |
| US20100022460A1 (en) | 2010-01-28 |
| AU2007252432A1 (en) | 2007-11-29 |
| RU2008150383A (ru) | 2010-06-27 |
| NZ573687A (en) | 2010-10-29 |
| WO2007136116A3 (en) | 2008-03-13 |
| AU2007252432B2 (en) | 2011-11-17 |
| EP2076503A2 (en) | 2009-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061026A1 (es) | Compuesto glicitol c-fenilo y preparacion farmaceutica | |
| AR060658A1 (es) | Derivados de diceto-piperazina y piperidina como agentes antivirales | |
| ES2521596T3 (es) | Combinación del compuesto GlyT1 con antipsicóticos | |
| AR064345A1 (es) | Derivados de 8-oxoadenina | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| AR040230A1 (es) | Indol, azaindol, y heterociclos relacionados de 4-alquenil piperidina | |
| AR061058A1 (es) | Derivados de piridopirimidininona. procesos de obtencion y composiciones farmaceuticas | |
| TW200617002A (en) | Novel substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | |
| AR040047A1 (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6 | |
| TW200738655A (en) | Novel bicyclic sulfonamide derivatives | |
| AR054882A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
| HUP0401784A2 (hu) | Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények | |
| ATE402174T1 (de) | Imidazopyridinderivate als kinaseinhibitoren | |
| BRPI0410714B8 (pt) | derivados de quinazolina macrocíclicos, seu processo de preparação, composição farmacêutica que os compreende e uso | |
| PE20040590A1 (es) | Composiciones de pirrolotriazina anilina como inhibidores de cinasa | |
| AR047817A1 (es) | Derivados de aril- y heteroarilpiperidincarboxilatos, su preparacion y su aplicacion en terapeutica | |
| TW200833324A (en) | Sulfonamide derivatives | |
| TW200745032A (en) | Novel heterobicyclic derivatives | |
| AR081252A1 (es) | Compuestos para el tratamiento del sindrome metabolico | |
| AR047974A1 (es) | Derivados de alquilpiperazina y alquilhomopiperazina-carboxilatos, su preparacion y su aplicacion en terapeutica | |
| AR079077A1 (es) | Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica de enfermedades mediadas por la tirosina quinasa | |
| AR049346A1 (es) | 3-amino-1-arilpropil-indoles como inhibidores de reabsorcion de monoaminas | |
| CO6160310A2 (es) | Nuevos derivados imidazolonas su preparacion como medicamentos composiciones farmaceuticas utilizacion como inhibidores de proteinas quinasas principalmente cdc7 | |
| NO20080033L (no) | Kinolinderivater som NK3-antagonister | |
| AR044821A1 (es) | 4-(aminometil)-piperidin benzamidas como antagonistas de 5ht4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |